Regarding DDR2, advances in nanomedicine by introducing a biomimetic stroma-modulating platform that combines co-deliver of DDR2-based CAF targeting with WRG-28 and a photothermal agent (IR-780), showed the efficacy of this dual-action strategy to suppress metastasis, induced CAF apoptosis, and dismantled the fibrotic barrier while preventing CAF repopulation in murine breast cancer models [121]. This evidence concerns the gene DDR2 and breast cancer.